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Abstract
Human aromatase (CYP19A1) is a steroidogenic cytochrome P450 converting androgens into estrogens. No ligand-free
crystal structure of the enzyme is available to date. The crystal structure in complex with the substrate androstenedione and
the steroidal inhibitor exemestane shows a very compact conformation of the enzyme, leaving unanswered questions on
the conformational changes that must occur to allow access of the ligand to the active site. As H/D exchange kinetics
followed by FTIR spectroscopy can provide information on the conformational changes in proteins where solvent
accessibility is affected, here the amide I region was used to measure the exchange rates of the different elements of the
secondary structure for aromatase in the ligand-free form and in the presence of the substrate androstenedione and the
inhibitor anastrozole. Biphasic exponential functions were found to fit the H/D exchange data collected as a function of
time. Two exchange rates were assigned to two populations of protons present in different flexible regions of the protein.
The addition of the substrate androstenedione and the inhibitor anastrozole lowers the H/D exchange rates of the a-helices
of the enzyme when compared to the ligand-free form. Furthermore, the presence of the inhibitor anastrozole lowers
exchange rate constant (k1) for b-sheets from 0.2260.06 min
21 for the inhibitor-bound enzyme to 0.1260.02 min21 for the
free protein. Dynamics effects localised in helix F were studied by time resolved fluorescence. The data demonstrate that the
fluorescence lifetime component associated to Trp224 emission undergoes a shift toward longer lifetimes (from <5.0 to
<5.5 ns) when the substrate or the inhibitor are present, suggesting slower dynamics in the presence of ligands. Together
the results are consistent with different degrees of flexibility of the access channel and therefore different conformations
adopted by the enzyme in the free, substrate- and inhibitor-bound forms.
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Introduction
Cytochrome P450s are heme-containing monoxygenases inter-
acting with a wide range of endogenous and exogenous substrates.
They are involved in several processes including vitamin and
steroid biosynthesis as well as detoxification of xenobiotics [1].
These enzymes recognise a wide range of molecules and possess
differently shaped and sized active sites, in some cases accommo-
dating even more than one molecule [2]. As an example, human
cytochrome P450 3A4 was shown to bind simultaneously two
molecules of the inhibitor ketoconazole in the active site of the
protein at the same time [2]. The crystal structures of some
mammalian cytochromes P450 in the presence and in the absence
of substrates or inhibitors have revealed that these enzymes can
adopt open and closed conformations [3,4]. For the bacterial P450
BM3, it was shown that helix movements and conformational
changes take place in the heme domain upon fatty acid binding
[5–8]. For the heme domain of this protein, different crystal
structures in the ligand-free form are present and revealed that
there is a rearrangement of helices, suggesting the presence of
different conformers in solution with a different degree of
accessibility of the active site [9]. Very recently, it has also been
shown a crucial role of the redox partner putidaredoxin in shifting
the bacterial cytochrome P450cam toward the open conformation
and favour proton-coupled electron transfer [10].
In the case of human aromatase, the cytochrome P450 acting in
the steroidogenesis by converting androgens in estrogens [11–13],
the crystal structure in complex with androstenedione has revealed
a very compact active site where the steroid molecule snugly fits
[14] and the catalytic pocket is optimized for androgens binding.
Its size (around 400 A˚3) is considerably smaller than that of other
P450 enzymes involved in drug and xenobiotic metabolism such as
3A4 (530 A˚3) or 2D6 (540 A˚3) [15,16]. Furthermore, the recently
solved crystal structures of aromatase in complex with steroidal
inhibitors revealed that some conformational movements at the
entrance of the substrate access channel take place, but the overall
structure is very similar to the one solved in the presence of the
substrate androstenedione, with a root mean square deviation
(RMSD) of 0.3 A˚ for the backbone atoms [17]. Aromatase has not
PLOS ONE | www.plosone.org 1 December 2013 | Volume 8 | Issue 12 | e82118
yet been purified in a stable form and crystallized in absence of
any ligand or in the presence of a non-steroidal inhibitor.
Molecular dynamics simulations have shown that, although the
catalytic cleft is very rigid, fluctuations of the F-G loop together
with bending and twisting motions contribute to open and close
the access channel of aromatase to allow the entrance of ligands
[18], but these in silico findings are not at present supported by
experimental data about the dynamics and flexibility of this
important enzyme.
Since conformational changes often play a crucial role in
substrate/inhibitor binding and catalysis, different approaches and
techniques have been applied to study the dynamics and flexibility
of cytochromes P450. They include NMR [19–21], crystal
structures in complex with the so-called molecular wires (22),
kinetics and termodynamic studies [23,24], pressure-induced UV-
vis spectral transitions [25,26], H/D exchange coupled with mass
spectrometry [27–29] and molecular dynamics simulations [30].
These studies have demonstrated that depending on the nature of
the ligand and on the P450 studied, multiple conformers can
simultaneously exist in solution upon ligand binding in some cases
[19,22,31–32] whereas, in other cases, the ligand can lock the
enzyme into a single conformational state and increase the rigidity
of the protein [33].
In a previous work, we demonstrated by a combined EPR and
Hyperfine Sublevel Correlation spectroscopic (HYSCORE) anal-
ysis that the inhibitor anastrozole binds to the heme iron of
aromatase via the triazole moiety and must therefore be able to
access the catalytic pocket of the enzyme [34]. In this work, we
report a straightforward protocol developed to obtain a protein
stable even in absence of any ligand and therefore suitable to be
studied by ATR-FTIR and time resolved fluorescence to
investigate how the dynamics and flexibility of the protein change
when a substrate or a non-steroidal inhibitor is added in the
catalytic cleft.
FTIR is a powerful tool to follow H/D exchange kinetics for a
wide range of proteins [35]. The time-course of the isotope
exchange can be followed by FTIR transmission experiments
either by dissolving lyophilized protein in deuterated water, or by
flowing deuterium-saturated nitrogen gas through a cell containing
the protein deposited on the germanium crystal of an attenuated
total reflection (ATR) device. Since mammalian cytochromes
P450 are membrane proteins difficult to manipulate and
lyophilized, the second option was applied for the first time to a
human cytochrome P450 that is an important drug target for
estrogen-dependent cancer.
Materials and Methods
Cloning, expression and purification of recombinant
human aromatase (rArom)
Human aromatase cDNA was N- and C-terminally modified
and cloned directly into a pCW Ori+ vector containing an IPTG-
inducible Tac promoter and an ampicilllin-resistance gene. Amino
acids 1–39 at the N-terminus of the protein sequence were
replaced by a 10 residues fragment containing positively charged
and hydrophilic amino acids (MAKKTSSKGR) as previously
described by Hong and co-workers [36]. At the C-terminus a four-
histidine tag was introduced to facilitate purification by affinity
chromatography.
The expression of recombinant aromatase (rArom) was carried
out in Escherichia coli strain DH5a. Competent cells were
transformed with the rArom clone and used to inoculate a 5 ml
Luria-Bertani (LB) liquid culture containing 100 mg/ml of
ampicillin. After 16 hours growth at 37uC, 5 ml of the liquid
culture were transferred to shaking flasks containing 0.5 L of
terrific broth (TB) medium supplemented with 100 mg/ml
ampicillin. Cells were grown to an OD600 of 0.5–0.8 before
induction with 1 mM IPTG and incubated with 0.5 mM d-
aminolevulenic acid for 48 hours at 28Cu. Cells were then
harvested and resuspended in 100 mM potassium phosphate
buffer pH 7.4 containing 20% glycerol, 1 mM b-mercaptoetha-
nol, 0.1% Tween-20. After 60 minutes of stirring at 4uC, 1 mM of
phenylmethylsulfonyl fluoride and 1 mg/ml lysozyme were added.
The detergent (Tween 20) concentration was then raised to 1%
and cells were disrupted by sonication on ice. After ultracentri-
fugation, the supernatant containing the soluble rArom was loaded
onto a diethylaminoethyl ion-exchange column (DEAE-Sepharose
Fast-Flow, GE healthcare) followed by a Nickel-ion affinity
column (Chelating sepharose Fast-Flow, GE healthcare). A linear
histidine gradient (1–40 mM) was applied to elute the protein.
Aromatase containing fractions were pooled and histidine
removed using a 30 kDa Ultracel centrifugal device (Amicon,
Millipore). The protein was stored at 220uC.
UV-vis spectroscopy
The P450 content of purified aromatase samples was measured
using reduced CO-difference spectra [37]. The CO binding assay
was performed in a 1 cm cuvette cell by following the increase of
the signal at 450 nm after reduction of rArom with sodium
dithionite and bubbling with CO for 10 minutes.
The absorbance at 450 nm was recorded by an Agilent 8453E
UV-Vis spectrophotometer and the iron (II)-CO complex amount
was estimated by using an extinction coefficient at 450 nm of
91,000 M21 cm21 [37].
Binding of androstenedione and anastrozole to the active site of
rArom were monitored spectroscopically as a shift of the
absorbance maximum from 418 nm to 394 nm for androstenedi-
one and from 418 nm to 422 nm for anastrozole. Increasing
concentrations of androstenedione or anastrozole (from 0.1 mM to
10 mM) were added to rArom in 100 mM potassium phosphate
pH 7.4, 20% glycerol, 0.1% Tween 20, 1 mM b-mercaptoetha-
nol. After equilibration the spectrum was recorded by a diode
array UV-vis spectrophotometer (Agilent 8453E, Agilent Tech-
nologies). The dissociation constant KD was calculated using the
equation:
(DA394=422{DA418)~
½(A394=422{A418)MAX½LFREE)=(KDz½LFREE)ð1Þ
where [L]FREE is [L]added-[EL] and [EL] = (DA394/4222DA418)
[P450]/(DA394/4222DA418) MAX.
The samples of rArom in complex with the substrate
androstenedione and the inhibitor anastrozole were prepared
through an overnight incubation of the protein with 10 mM of
androstenedione or 1 mM of anastrozole at 4uC.
Activity assay
Aromatase activity assay was carried out by the water release
method [38]. The protein (30 nM) purified in absence of substrate
was incubated with 30 nM of human cytochrome P450-reductase
(Invitrogen) with 500 nM of the substrate 1-b-H3-androstenedione
(Perkin Elmer). The reaction was then started by the addition of
1 mM NADPH and the mixture incubated for 10 minutes at
37uC. The reaction was then stopped by the addition of
trichloroacetic acid (50% v/v) and the protein precipitated by
centrifugation. The supernatant was then applied to a Strata X
(1)
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SPE column (Phoenomenex) for the separation of the androstene-
dione from the water phase.
The water phase was then counted by a Tri-Carb 2100TR
liquid scintillation analyzer (Packard Bioscience). Control exper-
iments were performed by omitting cytochrome P450-reductase to
the reaction mixture for each substrate concentration.
Thermal stability
Circular dichroism (CD) spectra of rArom were collected in the
far-UV range (200–250 nm) at a concentration of 1 mM using a
0.1 cm pathlength cell. Spectra were recorded at room temper-
ature on a Jasco-815 instrument (Jasco Instruments). Both the
buffer and the substrate androstenedione resulted not to affect the
spectra at the concentration used for the experiments with rArom
plus substrate.
Thermal denaturation experiments were performed by raising
the temperature from 25 to 70uC and allowing the protein sample
(1–3 mM) to equilibrate for 3 minutes at each temperature before
recording the spectrum. The CD signal at 208 nm was plotted as
function of temperature and the data fitted to a single step
transition curve to derive the melting temperature (Tm). Five
independent curves were considered for each sample (rArom,
rArom+androstenedione and rArom+anastrozole) to derive the
mean and the standard deviation for each experimental point.
Fluorescence spectroscopy
Static fluorescence measurements were carried out using a ISS
spectrofluorometer (ISS, Champaign, IL, USA). The protein
sample (5 mM) was excited at 293 nm and the emission spectrum
recorded from 310 and 450 nm.
Dynamic fluorescence measurements were carried out on 3–
5 mM protein samples with a K2 ISS spectrofluorometer (ISS,
Champaign, IL, USA) with a laser diode source. The excitation
wavelength was 300 nm, and the emission signal was collected
through a WG320 cut-off filter.
ATR-FTIR spectroscopy
Infrared spectra of aromatase were acquired using attenuated
total reflectance (ATR) tool (Harrick Scientific Products, Pleasant-
ville, NY) in a Bruker Model Tensor 27 FT-IR spectrometer
(Bruker Instruments, Billerica, MA) with a scan velocity of 10 kHz
and a resolution of 4 cm21. A thin protein film is deposited on an
internal reflection element. All spectra were collected from 4000 to
800 cm21. Data were collected in triplicate and spectra were
averaged, using the Opus software (Bruker Instruments, Billerica,
MA). Spectra of the protein were corrected by subtraction with
control samples acquired under the same scanning and temper-
ature conditions. The amide I band was corrected for the
contribution of aromatic amino acids and then deconvoluted
using PeakFit software (SPSS Inc., USA).
Kinetics of H/D exchange
For hydrogen/deuterium exchange, nitrogen gas was saturated
with 2H2O by bubbling through a bottle containing 200 ml of
2H2O.
The protein sample (20 ml of 100–150 mM) was placed on the
germanium crystal of the ATR tube in a home-made cell. At the
zero time, the tubing carrying nitrogen saturated with 2H2O was
connected to the cell. Spectra were recorded at 24uC every 60
seconds for the first 10 minutes and at 8 minutes intervals up to
200 minutes. Twenty scans were recorded and averaged for each
time point.
The H-D exchange was monitored by following the changes in
the amide I band, In order to dissect the contribution of the
different elements of the secondary structure, second derivative
spectra were considered. The relative intensity change was
considered and plotted as function of time. Fitting to exponential
curves were performed by using Sigma Plot software. Statistical
analysis for significance on the H/D exchange rate constants was
performed by T-test.
Results
Preparation, stability and activity of ligand-free form of
rArom
Although human aromatase has been cloned and expressed in
heterologous systems by other groups [36,39–42], many difficulties
have been encountered in obtaining a stable ligand-free enzyme.
For this reason the procedures reported to date involve the
addition of substrates or inhibitors during the purification process
with the aim of stabilising the active folded state of the protein.
Though viable, this approach leads to a difficulty in the full
removal of the ligands that results in sample heterogeneity due to
the co-existence of different spectroscopic species. As a conse-
quence, the first objective of the present work is to present data
from a new system that includes expression in a pCW vector in
E.coli DH5a and a new purification procedure able to give 15–
20 mg of pure protein per litre of liquid culture in a stable ligand
free-form of the enzyme. Very recently, the method has also
allowed to obtain crystals from the protein co-purified with the
substrate androstenedione and the crystal structure of recombinant
aromatase was solved and demonstrated an almost complete
superimposition with the placental one [43].
The purified protein shows the typical Soret maximum at
418 nm and the a and b bands at 535 and 571 nm, respectively
(Figure 1A).
The difference spectrum Fe(II)-CO minus Fe(II) of a sample of
aromatase purified in the absence of any ligand shows the typical
peak at 450 nm whereas no P420 species is detected (Figure 1B).
Thermal unfolding studies were performed and followed by far
UV circular dichroism (CD) spectroscopy. The CD signal at
208 nm was recorded in the temperature range 25–70uC after
allowing the sample to equilibrate for 3 minutes at each
temperature (Figure S1). The unfolding process leads to a typical
cooperative single step sigmoidal curve for all the samples analysed
(Figure 2D). The unfolding process results irreversible suggesting
protein aggregation during denaturation and problems related to
the loss of the heme as previously observed for other cytochromes
P450 [44] Therefore the unfolding transition temperature is
presumed as apparent [45] and determined to be 52.960.3uC for
the free rArom that indicates a stable protein on which to perform
binding studies.
All together these results show that rArom was indeed purified
in a stable form in the absence of added substrates or inhibitors
during the purification procedure. This enzyme is therefore
further characterised in terms of ability to bind a substrate and an
inhibitor, stability in the presence of ligands and catalytic activity.
After incubation of the protein with saturating amounts of the
substrate androstendione (10 mM) or the inhibitor anastrozole
(1 mM), the typical spectral transitions of cytochromes P450 for
type I (androstenedione) and type II (anastrozole) ligands are
observed (Figure 1A).
Upon androstenedione binding the Soret maximum completely
shifts to 394 nm and the a and b bands to 513 and 543 nm
respectively, with a charge transfer band at 643 nm typical of the
iron in a high spin state (Figure 1A). This shift reflects the low-to-
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high spin transition of iron due to the displacement of the water
molecule acting as the sixth axial ligand [46]. The Soret maximum
of aromatase in the presence of anastrozole is detected at 422 nm
(Figure 1A), with a and b bands at 535 and 571 nm, respectively.
Titrations with increasing amounts of the substrate androstenedi-
one (Figure 1C) and the inhibitor anastrozole were performed to
measure the dissociation constants that result 1.260.1 mM and
0.2960.03, respectively.
The stability of the ligand-bound protein was studied by CD
thermal unfolding studies performed in the same conditions of the
ligand-free form described above.
The unfolding process led to typical cooperative single step
sigmoidal curves from which unfolding transition temperatures
(Tm) were found to be 55.760.3uC and 52.660.4uC for the
substrate– and inhibitor-bound forms respectively, indicating a
small stabilizing role of the substrate. As these values are very close
to those found for the free-enzyme, they further demonstrate that
the protein was purified in a stable form even in the absence of a
ligand.
The specific activity of rArom purified in absence of any
substrate/inhibitor resulted 19.8 nmol/min/mg of protein. This
value is comparable to the one of the protein purified in presence
of androstenedione (16.4 nmol/min/mg of protein) and to that
reported for placental wild type aromatase (10 – 100 nmol/min/
mg of protein) (14). The presence of 1 mM of anastrozole resulted
in an almost complete inhibition of the protein activity (,5%).
ATR-FTIR spectroscopy and H/D exchange
The FTIR spectrum of rArom after 200 minutes of flowing
2H2O-saturated nitrogen gas in the cell containing the protein
sample deposited on the ATR surface is shown in Figure 2A. The
band at 1648 cm21 is assigned to the amide I primarily due to
stretching of the peptide C = O group, while the band at
1455 cm21 is assigned to the amide II that corresponds to the
N–H bending coupled with C–N stretching [35]. The signal at
1739 cm21 was previously detected in P450cam and was assigned
to the C = O stretch vibration of the carboxyl group of aspartic
and glutamic acid residues or to the heme propionates [47]. The
signal arising from tyrosine residues is also detected at 1517 cm21
[48].
The FTIR spectra of the samples of aromatase in complex with
the substrate and the inhibitor do not show any significant
Figure 1. Absorption spectroscopy of rArom. A) Visible absorption spectrum of 3.8 mM rArom in the absence of substrate (thick black line) and
in the presence of 10 mM of the substrate androstenedione (thin black line) and 1 mM of the inhibitor anastrozole (grey line). B) Difference spectrum
of Fe(II)-CO minus Fe(II) of rArom purified in absence of any substrate/inhibitor. C) Binding curve of androstenedione (inset: spectra recorded during
substrate titration). D) Thermal denaturation of rArom in the absence (squares), and in the presence of the substrate androstenedione (circles) or the
inhibitor anastrozole (triangles) monitored as a decrease in ellipticity at 208 nm in the far-UV CD spectra. The data were fit to a two-state transition to
obtain Tm for rArom in the absence (light grey curve), and presence of the substrate androstenedione (dark grey curve) or the inhibitor anastrozole
(black curve).
doi:10.1371/journal.pone.0082118.g001
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difference compared to the ligand-free sample. However, possible
modifications in the protein secondary structure induced by the
presence of the substrate/inhibitor were investigated by analysing
the amide I band, that it is used to estimate the amount of the
secondary structure elements in proteins.
Fitting of the amide I signal to a sum of nine Gaussians was
carried out as previously reported in the literature for other
cytochromes P450 (Figure 2B) [49]. Comparison of the raw data
(solid line) with the sum of the fitted Gaussians (dashed line) shows
a very good agreement. The areas for each component lead to the
assignments reported in table 1 that show that the data are within
the range of those found in the literature confirming the viability of
our protein samples. The results also show that addition of
androstenedione or anastrozole does not alter the rArom
secondary structure, as also confirmed by the far UV region of
the CD spectra of free and bound rArom that show a complete
overlap (data not shown).
FTIR spectroscopy was also used to determine the kinetics of
H/D exchange at 24uC over a time of 200 minutes (Figure 3). In
order to exclude possible denaturation effects, the amide I signal
was deconvoluted at the end of each repeat experiment to verify
the presence of the same secondary structure elements reported in
Table 1. Furthermore, the absorption spectrum in the visible
region was checked to verify the presence of the added ligands and
the correct folding of the protein. Moreover CO-binding to the
reduced protein was performed to confirm the presence of the
structurally unmodified P450 enzyme at the end of each
experiment.
Figure 3A shows the spectra recorded during H/D exchange for
a sample of rArom. Both the amide I and amide II bands are
found to shift towards shorter wavenumbers, from 1655 to 1649
and from 1549 to 1455 cm21, respectively.
In order to follow the H/D exchange of the secondary structure
elements, the second derivative spectra were generated and the
Figure 2. FTIR spectrum of rArom in D20. A) FTIR spectrum of rArom obtained by depositing 20 ml of rArom (135 mM in 100 mM KPi pH 7.4 +
20% glycerol + 0.1% Tween 20 + 1 mM b-mercaptoethanol) on the germanium crystal of the ATR accessory. B) Deconvolution of the amide I band
signal (thick line) into its nine components (thin lines). The experimental (solid thick line) and the predicted (dashed line) spectra are shown.
doi:10.1371/journal.pone.0082118.g002
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intensity of the signals at fixed wavelength corresponding to the
different elements of the secondary structure are followed as a
function of time (Figure 3B) [50]. In particular, in line with the
assignments found in literature [49] the signal at 1655 cm21 was
followed for the a-helices, at 1623 cm21 for the b-sheets and at
1640 cm21 for random coils. The signal of the a-helices is found
to decrease and shift toward lower wavenumbers during H/D
exchange, while the signal of the b-sheets resulted to increase. The
intensity change of each spectrum recorded during H/D exchange
for 200 minutes for the 1655, 1623 and 1640 cm21 signals is than
plotted as a function of time. Experimental data were found to
follow exponential kinetics, as expected for protein deuteration,
and were found to better fit to the sum of two exponential decay
functions (Figures S2-S4) suggesting the presence of two popula-
tions of protons with different exchange rates in all the samples.
The values found for the rate constants are in keeping with the
literature data [51–54] and indicate that the H/D exchange rate
constants of the fastest exchanging protons on the protein surface
fall in a timescale not detected by the experiment. On the other
hand the first one (k1, Table 1) is assigned to the exchange of
flexible partially exposed protons and the second one (k2, Table 2)
to the protons in flexible buried regions [51–54]. Statistical
analysis of the values shows that significant differences in both k1
and k2 values for a-helices were found in rArom complexed with
androstenedione and anastrozole when compared to the free form.
Significant differences were observed in both H/D exchange rates
(k1 and k2) of the b-sheets only for the protein complexed with
anastrozole.
Fluorescence spectroscopy
The steady-state emission fluorescence spectra of rArom are
reported in figure 4. The spectral shape and intensity of the wild-
type rArom are strongly influenced by the presence of the
substrate or the inhibitor (Figure 4A). Analysis of the protein 3D
structure shows that human aromatase contains 5 Trp residues
(Trp67, Trp88, Trp141, Trp224 and Trp239), but only one
(Trp224) is part of the active site. In particular, it is located in helix
F and it entertains van der Waals contacts with the substrate
androstenedione [14]. For this reason the mutant Trp224Phe was
generated and, in this case, no significant changes were detected
upon ligands binding (Figure 4D). When compared to the wild-
type rArom, this mutant shows a higher dissociation constant for
both androstenedione (4.660.3 mM) and anastrozole
(0.5960.03 mM) and therefore 50 mM of androstenedione and
3 mM of anastrozole were added to reach saturation. The activity
of the mutant resulted also decreased by 35% compared to the
non-mutated protein.
Taking advantage of the sensibility of time resolved fluorescence
techniques, we further characterized the effects observed in the
steady-state measurements, performing a set of parallel experi-
ments using the phase-shift and demodulation methodology
(Figure 4B and 4E).
A complex, multi-exponential emission decay is necessary to
adequately fit the data. In particular, according to the lower chi-
square value (Table S1), the best fit was obtained using a four
components model, with lifetimes (t) centered at 0.55 (t1), 2.2 (t2),
5.1 (t3), and 9.2 (t4) ns for the ligand-free enzyme (Figure 4C).
The addition of the 10 mM androstenedione or 1 mM
anastrozole to rArom results in a shift of t2 and t3 towards longer
values (Figure 4C) and a significant decrease of the fraction
percentage of the emitting species of the third component.
Due to its presence in the ligand-binding site and its ability to
closely interact with the bound ligand, it is reasonable to expect
Table 1. Amount of secondary structure elements (%)
present in rArom and comparison with the values reported in
literature for other P450 enzymes.
Protein b-sheet
310-helix +
random ~ahelix b-turn
rArom 2661 1665 3763 2263
rArom +
substrate
2564 1862 3864 1962
rArom +
inhibitor
2264 1762 3865 2363
CYP101a 22 12 34 31
CYP111a 18 20 46 17
CYP102a 24 17 38 21
CYP2B4a 19 20 35 26
CYP11A1a 26 11 36 27
afrom ref. [49].
doi:10.1371/journal.pone.0082118.t001
Figure 3. FTIR spectra of rArom during H/D exchange. A) Spectra recorded as a function of time after connecting the sample cell with a
2H2O-saturated nitrogen flow. The spectra are normalized for the amide I signal. B) Second derivative spectra obtained from the FTIR spectra
recorded as a function of time. The signals at 1655, 1623 and 1640 cm21 are assigned to a-helices, b-sheets and random coil, respectively [49].
doi:10.1371/journal.pone.0082118.g003
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that Trp224 is contributing the most to the t2 and t3 components
that are significantly affected by ligand binding.
When a four discrete components model is used to fit the data of
the Trp224Phe mutant, the fraction of t3 results to be decreased to
a negligible signal of less than 1%, demonstrating that this
component is specific for Trp224. The addition of the andro-
stenedione or anastrozole to the Trp224Phe mutant does not
significantly perturb the three remaining t components
(Figure 4D). These data prove that the change of t3 observed
upon ligand addition to rArom is related to the presence of
Trp224. As changes in fluorescence lifetimes are known to be
linked to changes in the dynamics of the fluorophores that
generates them, these results indicate that the dynamic of Trp224
is affected by ligand binding. The presence of the t2 component in
the Trp224Phe mutant indicates that this component is due to
more than one Trp residue. It is, in fact, well established that a
single Trp residue can contribute to more components of t [55]. It
is important to note that Trp224 is located in helix F, that in other
cytochromes P450 is found to be flexible to allow substrate
entrance [56]. From these observations it follows that also in
rArom the F-helix is involved in some conformational changes that
are key to allow access of the ligand into the binding site. In
alternative, it could be argued that the substitution of the
tryptophan residue with a phenylalanine produces a more
compact local tertiary structure, making the other tryptophans
insensitive to the presence of both substrate and inhibitor. This
possible explanation is in keeping with the different KD values
found for wild-type rArom and the Trp224Phe mutant.
Table 2. H/D exchange rates of the secondary structure elements.
a-helix b-sheet Random coil
k1 (min
21) k2 (min
21) k1 (min
21) k2 (min
21) k1 (min
21) k2 (min
21)
rArom 0.1360.01 0.0760.01 0.2260.06 0.0260.001 0.3860.04 0.0260.001
rArom+sub 0.0960.02** 0.0260.001** 0.2160.03 0.0260.001 0.4760.05 0.0260.001
rArom+inhib 0.0760.01** 0.0260.002** 0.1260.02** 0.0260.001* 0.4360.06 0.0160.002
**P,0.001 in comparison to the value for rArom.
*P,0.005 in comparison to the value for rArom.
doi:10.1371/journal.pone.0082118.t002
Figure 4. Fluorescence properties of rArom and the mutant Trp224Phe. A) Steady-state fluorescence emission spectra (lexc = 293 nm) of
rArom in the absence (solid line) and in the presence of the substrate androstenedione (dashed line) or the inhibitor anastrozole (dotted line). B)
Phase-shift and demodulation data of rArom in the absence (squares), and in the presence of the substrate androstenedione (circles) or the inhibitor
anastrozole (triangles). C) Fluorescence lifetimes obtained from the fitting of the experimental data to a four discrete components model for rArom in
the absence (black bars), and in the presence of the substrate androstenedione (dashed bars) or the inhibitor anastrozole (dotted bars). Panels D), E)
and F) use the same symbols to show the results obtained under the same conditions for mutant Trp224Phe.
doi:10.1371/journal.pone.0082118.g004
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Discussion
Ever since the publication of the crystal structure of human
placental aromatase that revealed a very compact nature of the
enzyme in the presence of the substrate androstenedione, one of
the key questions is how the protein undergoes conformational
changes to allow the entrance of different ligands in the tight active
site [57]. The difficulty of obtaining a purified protein without the
addition of any ligand hindered experiments aiming at addressing
this question. For this reason one of the key aspects of this present
work is the successful achievement of a recombinant system that
allows to purify human aromatase in the absence of any substrate/
inhibitor. Ligand-free thermal unfolding data of recombinant
aromatase reveal Tm values similar to those reported before for
other mammalian cytochromes P450 [45]. Furthermore, the
addition of the substrate androstenedione results to increase the
Tm by 3uC suggesting the presence of protein-substrate interac-
tions that stabilise the protein. This is consistent with the crystal
structure showing the presence of both hydrophobic and polar
interactions between androstenedione and different residues of the
catalytic cleft of the protein. However, this kind of stabilization is
not observed in the presence of the inhibitor anastrozole that is
bound to the protein through direct coordination of the heme iron
by the nitrogen atom of the triazole moiety [34]. The protein
complexed with anastrozole also displays a different behaviour in
the H/D exchange experiments with respect to the form
complexed with the substrate androstenedione. The H/D
exchange rates for -sheets are lower in the presence of the
inhibitor, suggesting a perturbation of these elements. Further-
more, time resolved fluorescence data show that the fluorescence
dynamics of Trp224, located in helix F (Figure 5B), is less affected
by anastrozole binding, in comparison to the binding of
androstenedione. In fact, in the case of the substrate, the componet
t3 almost completely disappears whereas, in the presence of the
inhibitor anastrozole, is only reduced by 50%. Analysis of the
crystal structure reveals that Helix F (cyan in Figure 5) is part of
the substrate access channel that, according to molecular dynamics
simulations, encounter hinge-bending motions likely to be
responsible for its intrinsic flexibility [18]. The channel is also
formed by helix I, part of helix E and b-sheet 3 (Figure 5A).
Unfortunately to date there is no crystal structure of the enzyme
in complex with the inhibitor, preventing a direct comparison of
the different effects that inhibitor or substrate binding have on the
crystal structure. However MD simulations [18] show that the
substrate access channel is formed by part of helix F, I and E and
b-sheet 3 (Figure 5A). This confirms that both elements of
secondary structure (a-helices and b-sheets) are involved, as found
by ATR FT-IR findings, and that helix F is involved in anastrozole
binding as indicated by fluorescence spectroscopy.
In conclusion, this work reports the first study of the dynamics
and flexibility of ligand-free aromatase. Taken together our results
show that aromatase flexibility is decreased by the addition of a
ligand: different H/D exchange rates for b-sheets and localized
dynamics effect on Trp224 suggest a different effect on the
conformation given by the substrate androstenedione and the
inhibitor anastrozole. The different degree of flexibility observed
between the ligand-free and -bound forms is compatible with the
hypothesis of the presence of an open conformation in the ligand-
free form.
Supporting Information
Figure S1 Far-UV circular dichroism spectra of a
sample of rArom at increasing temperatures.
(TIF)
Figure S2 Deuteration of a-helices as function of time.
A) Data for ligand-free rArom and fitting to a double exponential
decay (first exponential decay R2 = 0.9983, second exponential
decay R2 = 0.9912). B) rArom in the presence of androstenedione
with fitting to a double exponential decay (solid line, R2 = 0.9989)
and a monophasic exponential decay (dashed line, R2 = 0.9840).
C) rArom in the presence of anastrozole with fitting to a double
exponential decay (first exponential decay R2 = 0.9994, second
exponential decay R2 = 0.9960).
(TIF)
Figure S3 Deuteration of b-sheets as function of time. A)
Data for ligand-free rArom and fitting to a double exponential
decay (first exponential decay R2 = 0.9989, second exponential
decayR2 = 0.9964). B) rArom in the presence of androstenedione
with fitting to a biphasic exponential decay (solid line, (first
Figure 5. Access channel of rArom for the substrate androstenedione. A) Overall structure of rArom (PDB ID 4KQ8). The most flexible regions
according to the MD simulations [18] are shown in red. The parts of the secondary structure elements forming the access channel are shown in yellow
(helix E), cyan (helix F), orange (helix)I, magenta (b-strand 9). B) Zoom in the active site: the heme is shown in red, the Van der Waals surface of
androstenedione (blue) and Trp224 (grey) are also shown.
doi:10.1371/journal.pone.0082118.g005
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exponential decay R2 = 0.9998, second exponential decay
R2 = 0.9952). C) rArom in the presence of anastrozole with fitting
to a biphasic exponential decay (first exponential decay
R2 = 0.9980, second exponential decay R2 = 0.9864).
(TIF)
Figure S4 Deuteration of random coil as function of
time. A) Data for ligand-free rArom and fitting to a double
exponential decay (R2 = 0.9957) and a monophasic exponential
decay (dashed line, R2 = 0.8608). B) rArom in the presence of
androstenedione with fitting to a biphasic exponential decay (solid
line, R2 = 0.9976) and a monophasic exponential decay (dashed
line, R2 = 0.8403). C) rArom in the presence of anastrozole with
fitting to a biphasic exponential decay (R2 = 0.9865) and a
monophasic exponential decay (dashed line, R2 = 0.8322).
(TIF)
Table S1 Chi-square values of the fitting of the time resolved
fluorescence data to different exponential components.
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